Key facts
- It has raised $19.8M.
- Notable investors include Enterprise Ireland, European Commission, Western Development Commission, Boole Investment Syndicate, DeepIE Ventures — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Ovagen
- ·The full record, as it builds
Funding rounds
No funding rounds for Ovagen are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ovagen
Operator of a veterinary company intended to develop a process of producing germ-free eggs in commercial quantities, used primarily in healthcare industries. The company's process facilitates large-scale production of recombinant proteins to GMP standard using a transgenic chicken platform, enabling pharmaceutical companies to have a safe, biosecure, large-scale, flexible, and cost-effective biomanufacturing platform for the production of vaccines and therapeutic proteins.
- Sector
- Healthcare
- HQ
- Ballina, Ireland
- Founded
- 2000
- Employees
- 13
- Website
- ovagen.ie/
- Ownership
- Privately Held (backing)
Ovagen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ovagen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ovagen in its N-PORT filings yet. We sweep new filings monthly.